Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab
Alector Inc. (NASDAQ:ALEC) is one of the best stocks under $3 to invest in.
Alector Inc. (ALEC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 4,318,109 | $8,679,399 | +54% | 0.28% |
| 2. | Kynam Capital Derrick Tang | 3,808,494 | $7,655,073 | +91% | 0.42% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 3,247,426 | $6,527,326 | +11% | 0.01% |
| 4. | 683 Capital Partners Ari Zweiman | 3,200,000 | $6,432,000 | 0.32% | |
| 5. | D E Shaw D. E. Shaw | 2,959,983 | $5,949,566 | -12% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.00 | 20,000 | $500,000.00 | 44,621 | 2020-02-03 | Filing | |
| $19.00 | 203,200 | $3,860,800.00 | 203,200 | 2019-02-11 | Filing | |
| $19.00 | 50,561 | $960,659.00 | 2,455,853 | 2019-02-11 | Filing | |
| $19.00 | 157,939 | $3,000,841.00 | 10,434,976 | 2019-02-11 | Filing | |
| $19.00 | 203,200 | $3,860,800.00 | 203,200 | 2019-02-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.97 | 87,216 | $172,190.55 | 2,367,206 | 2026-06-02 | Filing | |
| $1.88 | 3,475 | $6,542.73 | 95,461 | 2026-06-03 | Filing | |
| $1.97 | 5,709 | $11,270.71 | 98,936 | 2026-06-02 | Filing | |
| $1.97 | 19,360 | $38,220.51 | 379,900 | 2026-06-02 | Filing | |
| $2.65 | 1,820 | $4,823.00 | 104,645 | 2026-04-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,000,000 | $20,100,000 | 0.48% | |
| 2. | 7,847,879 | $15,774,236 | 0% | |
| 3. | 4,009,340 | $8,058,773 | 0% | |
| 4. | 3,545,719 | $7,126,896 | 1.35% | |
| 5. | 2,820,493 | $5,669,191 | 0% |
News See All
10 Best Stocks Under $3 to Invest In
On October 16, Victoria Greene, Chief Investment Officer of G Squared Private Wealth Management, appeared on CNBC to state that small caps demonstrate lasting strength.
Alector, Inc. (NASDAQ:ALEC) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2025 Earnings Conference Call.
Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation
Alector Inc. (NASDAQ:ALEC) is one of the stocks under $10 to buy now. On July 28, Mizuho upgraded Alector from Neutral to Outperform, while raising the price target from $2.50 to $3.50.
10 Stocks Under $10 to Buy Now
Earlier on July 1, Peter Kraus, Aperture Investors chairman and CEO, joined 'Squawk Box' on CNBC to suggest that the small and mid-cap area is a place for significant growth.
Alector, Inc. (NASDAQ:ALEC) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Alector, Inc. (NASDAQ:ALEC) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call. At this time, all participants are in listen-only mode.
10 Best Biotech Penny Stocks to Buy Now
In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities.
Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. beats earnings expectations. Reported EPS is $-0.49, expectations were $-0.8. Alector, Inc.
Alector, Inc. (NASDAQ:ALEC) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Alector Midyear 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Hedge Fund Resource Center